Protecting Innovation: Proposed Reforms Threaten US Pharmaceutical Leadership
Robust property rights and calibrated regulations have long been key ingredients of the U.S. life-sciences ecosystem, facilitating the development of new drugs that require substantial investments in research, development, and commercialization. Recent legislative proposals, however, threaten to undermine this system under the guise of addressing drug-pricing concerns.
Of particular concern in the current legislative landscape are S. 2780, the Medication Affordability and Patent Integrity Act, and S. 2305, the Biosimilar Red Tape Elimination Act, both of which are currently scheduled to be considered in a Sept. 26 markup session of the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee. While ostensibly designed to improve drug affordability and bolster market competition, these bills risk disrupting the delicate balance that has made the United States a global leader in pharmaceutical innovation.